|
|
 |
|
Viewing report
|
|
|
|
Parkinson's Disease Biomarkers: Vital Tools for Neuroprotectants
Decision Resources, Inc, Nov 2006, Pages: 32
Parkinson’s disease (PD) is poised to become a significant public health burden as the population ages. We expect the number of PD cases in the seven major drug markets we cover to reach nearly 3.6 million in 2015, yet no therapy is available to treat the disease. Thus, the PD market provides significant opportunity for disease-modifying drugs, but their potential will not be fully realized without a biomarker that permits diagnosis of the disease in its early stages, when disease-modifying therapies would be most effective.
Get the Answers You Need to Shape Your Strategy
By the time symptoms progress to the point where a physician diagnoses PD, up to 70-80% of dopaminergic neurons are lost. A biomarker would allow a PD patient to receive a diagnosis and start treatment years earlier. What are the difficulties in diagnosing PD, and why are early diagnosis and treatment so important? What are the limitations of current treatments for PD? Several manufacturers are investigating imaging and genetic markers as diagnostic agents. What value does a PD biomarker offer? What diagnostic markers are emerging, and what challenges do they face? How might these agents impact the U.S. PD market? Disease-modifying (neuroprotectant) drugs can slow the progression of PD, but only two such drugs are expected to launch over the next ten years. The success of these drugs hinges on the development of a diagnostic marker. How are biomarkers impacting the development of neuroprotectants? Which drug manufacturers would benefit most from the launch of a biomarker?
Scope
Pathophysiology of Parkinson’s disease (PD): etiology and clinical symptoms, use of biomarkers.
Value of biomarkers for PD: benefits and limitations of biomarkers and their effects on current and emerging PD therapies.
Emerging imaging agents for PD diagnosis: DaTSCAN, Altropane, Dopascan.
Market implications: concurrent drug/diagnostic development, hurdles to market, and the impact of PD biomarkers on neuroprotectant development.
Outlook: how biomarkers will increase the potential of the PD market.
Author: Andrea S. Witt, Ph.D.
Decision Resources, Inc
|
|
|
|
